Current stock page

Catalysts

OMER Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

OMEROmeros Corporation

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$17.49−$0.50 (−2.78%)

Latest quote

  • Momentum
    79
  • Value
    73
  • Quality
    55
  • Risk resilience
    33
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 16, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 64/100

Momentum 79/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment -4.46%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 79/100AIQ Edge 7/10 Above Peers
Beat rate
88%
7 of 8 reported periods
Average surprise
+119.4%
Across covered historical reports
Latest result
+155.9%
Aug 13, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Aug 13, 2026—-$0.27$0.15+155.9%$12.69M$28.53M
May 13, 2026—-$0.40-$0.24+40.0%$4.19M$9.9M
Mar 31, 2026—-$0.55$3.14+670.9%$1.6M—
Nov 13, 2025—-$0.58-$0.47+19.0%$312.5K—
Aug 14, 2025—-$0.55-$0.43+21.8%$312.5K—
May 15, 2025—-$0.57-$0.58-2.5%$400K—
Mar 31, 2025—-$0.78-$0.54+30.4%——
Nov 13, 2024—-$0.70-$0.56+20.0%——

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
2
Buy
1
Hold
12-month analyst target
$22.00
+25.79% versus current price
Based on 3 analyst observations. Targets are estimates, not predictions.
Low target
$22.00
+25.79% vs latest price
Average target
$22.00
+25.79% vs latest price
High target
$22.00
+25.79% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 16, 2026

Next known earnings or reporting date.

EPS estimate$0.02

Current analyst expectation for the upcoming report.

Revenue estimate$37.28M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score79

Where event reaction would show up first.

AIQ score64/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
3
Average target
$22.00
Target upside
25.79%
Target range
$22.00 - $22.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
1
Negative
2
seekingalpha.com · Oct 21, 2026

Omeros: The Trade After European Rejection (NASDAQ:OMER)

Omeros Corporation is positioned to dominate the TM-TMA market with Yartemlea, the only FDA-approved therapy for this indication. See why I rate OMER stock a hold.

gurufocus.com · Oct 16, 2026

H.C. Wainwright Maintains Buy on Omeros (OMER) Despite Regulatory Setback, Stock Drops 14%

On October 16, 2026, H.C. Wainwright reaffirmed its Buy rating on Omeros Corporation (NASDAQ: OMER) following a 14% decline in the stock after an unfavorable op

rttnews.com · Oct 16, 2026

Omeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab Opinion

Omeros Corporation (OMER) is down 12.03 percent, losing $2.26 to $16.53 on Friday. The decline follows a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on the company's marketing authorization application for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy.

gurufocus.com · Oct 16, 2026

Omeros (OMER) Faces EMA Setback on Narsoplimab Approval Amid Insider Selling Pressure

On October 16, 2026, Omeros Corporation (NASDAQ: OMER) received unfavorable feedback from the European Medicines Agency's Committee for Medicinal Products for H

finance.yahoo.com · Aug 20, 2026

Omeros (OMER) Q2 2026 Earnings Call Transcript

Yartemlia generated $32.2M in gross sales during its first full quarter on market.

Open full news and sentiment

OMER Catalysts FAQ

What are the next catalysts for OMER stock?

OMER's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move OMER stock?

Upcoming events that could move OMER include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could OMER's next earnings report affect the stock?

OMER's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive OMER stock higher?

OMER could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt OMER stock?

OMER could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.